President: Thomas Rösch

Friedrich HagenmüllerSiegbert Faiss

November 6 and 7, 2015Congress Center Hamburg

www.endoclubnord.com

Interventional endoscopy has undergone rapid development. Many patients who

would have required surgery not long ago can be easily treated via endoscopic

therapy now.

EMR, ESD, POEM, and stenting are only a few chapters of a success story that

gastroenterologists like you are writing every day. With innovative endoscopic

technologies – such as Dual Focus and NBI, coupled with a range of perfectly

matched endotherapy instruments – Olympus provides you with the tools you

need to provide targeted and effective treatment.

Discover more today at www.olympus-europa.com.

SEE AND TREATEndoscopic Intervention with Olympus

Figu

res:

Cou

rtes

y of

the

Ask

lep

ios

Klin

ik in

Ham

bur

g B

arm

bek

.

1353

7

Postbox 10 49 08, 20034 Hamburg, Germany | Phone: +49 40 23773-0 | www.olympus-europa.com

Anzeige_ECN_A5_Sprachen_20150309.indd 1 10.03.15 12:46

2 3

Distribution supported by Olympus Europa Holding GmbH.

TABLE OF CONTENTS

MOVIPREP®/MOVIPREP® ORANGE, Pulver zur Herstellung einer Lösung zum EinnehmenZusammensetzung: Beutel A enthält: Macrogol 3350 100 g, Natriumsulfat 7,5 g, Natriumchlorid 2,691 g, Kaliumchlorid 1,015 g; Beutel B enthält: Ascorbinsäure 4,7 g, Natriumascorbat 5,9 g. Hilfsstoffe MOVIPREP®: Aspartam, Acesulfam-Kalium, Zitronenaroma. Hilfsstoffe MOVIPREP® ORANGE: Aspartam, Acesulfam-Kalium, Orangenaroma. Anwendungsgebiete: Zur Darmvorbereitung vor klinischen Maßnahmen, die einen sauberen Darm erfordern, z.B. endoskopische oder radiologische Untersuchungen des Darms. Gegenanzeigen: Gastrointestinale Obstruktion oder Perforation, Störungen der Magenentleerung, Ileus, Phenylketonurie, Glukose-6-Phosphatdehydrogenase-Mangel, Überempfi ndlichkeit gegen die Wirkstoffe oder die sonstigen Bestandteile, toxisches Megakolon als Komplikation schwerer entzündlicher Darmerkrankungen. MOVIPREP®/MOVIPREP® ORANGE darf nicht bei bewusstlosen Patienten angewendet werden. Nebenwirkungen: Sehr häufi g: Abdominalschmerz, Übelkeit, abdominale Aufblähung, Analreizungen, Unwohlsein. Häufi g: Schlafstörungen, Schwindel, Kopfschmerzen, Erbrechen, Dyspepsie, Rigor, Durst, Hunger. Gelegentlich: Dysphagie, Leberfunktionstests anormal, Unbehagen. Nicht bekannt: Anaphylaxie, Krampfanfälle im Rahmen einer ausgeprägten Hyponatriämie, vorübergehender Anstieg des Blutdrucks, Flatulenz, Brechreiz, Pruritus, Urticaria, Hautausschlag, Elektrolytverschiebungen einschließlich Bikarbonatkonzentration im Blut vermindert, Hyper- und Hypocalciämie, Phosphatkonzentration im Blut vermindert, Hypokaliämie und Hyponatriämie (die beiden letztgenannten Störungen treten häufi ger bei Patienten auf, die gleichzeitig Medikamente einnehmen, die einen Einfl uss auf die Niere haben, wie z.B. ACE-Inhibitoren und Diuretika) sowie Änderungen der Chloridkonzentration im Blut. Handelsformen: Eine Anwendung besteht aus 2 Btl. A und 2 Btl. B. Packungsgrößen von 1 (N 1), 10, 40, 80, 160 und 320 Packungen einer einzelnen Anwendung. Klinikpackung mit 40 einzelnen Anwendungen. Apothekenpfl ichtig. Stand 07/2012

MOVIPREP, NORGINE and the sail logo are registered trademarks of the Norgine Group of companies.

VERTRAUENVERTRAUENDURCH KLARHEIT

MOVIPREP®

IHR PARTNER IN DER ERFOLGREICHEN DARMVORBEREITUNG.EFFEKTIV – VERTRÄGLICH – COMPLIANT1

1. Ell C. et al. American Journal of Gastroenterology 2008; 103(4):883-893.

Foreword 5

Program NEW: Workshops on Friday 6

Experts 9

General Information 16

Registration 17

Travel 19

Cooperation with Deutsche Bahn (German Railway) 20

Cooperation with Lufthansa Group Partner 21

Public Transportation – HVV-Map 23

City Map 25

Sponsors 27

Registration Form 29

ENDOCLUBNORD 2015

Download Program

Scientific Chairman and responsible for the editorial content:

Prof. Dr. Thomas RöschUniversitätsklinikumHamburg-Eppendorf

Design and Layout

Rosenheimer Str. 145c · 81671 Munich, Germanywww.cocs-media.de

COCS media does not guaranteethe correctness of information.

Friedrich Hagenmüller

Asklepios KlinikAltona

4 5

Thomas RöschPresident 2015Universitätsklinikum Hamburg-Eppendorf

Siegbert Faiss

Asklepios KlinikBarmbek

FOREWORD

CitraFleet® Pulver zur Herstellung einer Lösung zum Einnehmen in einem Beutel. Wirkstoffe: Natriumpicosulfat, leichtes Magnesiumoxid, wasserfreie Citronensäure. Zusammensetzung: 1 Beutel mit 15,08 g Pulver enth. 10,0 mg Natriumpicosulfat, 3,5 g leichtes Magnesi-umoxid und 10,97 g wasserfreie Citronensäure. Sonst. Bestandt.: Kaliumhydrogencarbonat, Saccharin-Natrium, Zitronenaroma (Zitro-nenaroma, Maltodextrin, RRR-α-Tocopherol E 307). Anwendungsgebiete: für Erwachsene ab 18 Jahren: zur Darmreinigung vor jeder diagnostischen Untersuchung, die nur bei einem gut gereinigten Darm sinnvoll durchgeführt werden kann (z.B. Koloskopie, Röntgen). Gegenanzeigen: Überempf. gg. Bestandt., dekomp. Herzinsuff., schwere Dehydrat., Hypermagnesiemie, Magenretention, Ulzerat. GIT, tox. Colitis, tox. Megacolon, Ileus, Übelkeit, Erbrechen, Aszitis, Appendizitis, Obstr./Perfor. GIT, Rhabdomyolyse, aktive Entzündung (Mor-bus Crohn, Colitis ulcerosa), eingeschr. Nierenfunkt. Warnhinweise: enthält 5 mmol Kalium. Nebenwirkungen: sehr häufig: Bauchschm. häufig: Schlafst., Kopfschm., Mundtrock., Übelkeit, Blähbauch, Analbeschw., Proktalgie, Durstgef., Müdigk., gelegentlich: Schwindel, orthostat. Hypot., Erbrechen, Stuhlinkont., Häufigk. n. bekannt: Anaphylaktoide Reakt., Überempf., Hyponatriämie, Epilepsie, Grand-mal-Anfall, Konvuls., Verwirrtheitszust., Durchfall, Flatulenz, Hautausschl., Urtikaria, Pruritus, Purpura, Schmerzen. Apothekenpflichtig. Stand: April 2012. Zulassungsinhaber: Laboratorios Casen-Fleet S.L.U., Autovía de Logroño Km 13,300, 50180 UTEBO, Zaragoza, Spanien. Mitver-trieb: Recordati Pharma GmbH, Eberhard-Finckh-Str. 55, 89075 Ulm.

• Duales Wirkprinzip durch zwei Wirkstoffe1

• Hohe Patientenverträglichkeit2

• Schmeckt angenehm nach Zitrone3

Für eine gründliche Entleerung und Reinigung1

1 Fachinformation CitraFleet® Stand 12/20102 Ciáurriz A, et al. Calidad de la colonoscopia: efectividad y

tolerancia de tres regimenes de limpieza. Poster presented at Semana de las Enfermedades Digestivas (SED) 11-14 de Junio, 2011. Sevilla, Spain.

3 Schirin-Sokhan R., Trautwein C., MMW Fortschritte der Medizin Originalien 2009; 151(1): 34-38

Zur Darmreinigung vor Koloskopien oder Röntgenuntersuchungen

Natriumpicosulfat + Magnesiumcitrat

REC-CITRA-006635 Anz Citrafleet DIN A5#RZ2.indd 1 18.02.15 16:21

PD Dr. Siegbert Faiss Prof. Dr. Thomas Rösch Prof. Dr. Friedrich Hagenmüller

Welcome to the 23rd ENDOCLUBNORD!

Dear guests and endoscopy experts,

We look forward to welcoming you to the 23rd ENDOCLUBNORD in Hamburg on November 6 and 7, 2015. Again this year, we will be demonstrating the latest developments in flexible gastroenterological endoscopy. This ENDOCLUBNORD will focus in particular on inter-faces between endoscopy and histopathology as well as minimally invasive surgery. You will be able to see many exciting live cases, followed by case discussions on Saturday. For the first time, Friday evening will be finished with high-class workshops with possibilities to get direct answers to all your questions. Gastrointestinal pathology has always been our gold standard es-sentially backing up diagnostic endoscopy. The exciting develop-ment of endoscopic imaging, resulting in super-high resolutions and details, allows us to view structures that almost seem to match tissue diagnosis. We also have a long and fruitful relationship with minimally invasive surgery, another area where see continuous pro-gress.We wish to work on and discuss all these questions with you.

Come to Hamburg, Germany’s premiere location for endoscopy, on November 6 and 7! We look forward to seeing you there!

6

FRIDAY, NOVEMBER 6, 2015

7

FRIDAY, NOVEMBER 6, 2015

9.00 – 9.15 a.m. Opening and Introduction President: Thomas Rösch, Hamburg Honorary President: Manfred Stolte, Kulmbach Honorary Member: Kazuhiro Saito, Tokyo, Japan

9.15 – 10.10 a.m. Endoscopy live, Part 1 Live Video Broadcast from the three Hospitals: Asklepios Klinik Altona, Asklepios Klinik Barmbek and Universitätsklinikum Hamburg-Eppendorf

10.10 – 10.30 a.m. IBD – Update 2015: endoscopy, diagnostics, therapy Axel Dignaß, Frankfurt AbbVie Lecture

10.30 – 11.15 a.m. Endoscopy live, Part 2

11.15 – 11.45 a.m. Coffee Break in the Industry Exhibition

11.45 – 12.40 p.m. Endoscopy live, Part 3 12.40 – 01.00 p.m. Liver cirrhosis – a malignant disease Ansgar Lohse, Hamburg Norgine Lecture

01.00 – 01.50 p.m. Lunch Break in the Industry Exhibition

01.50 – 02.50 p.m. Endoscopy live, Part 4

02.50 – 03.10 p.m. New specific mechanisms in IBD therapy – perspectives Britta Siegmund, Berlin Takeda Lecture 03.10 – 04.00 p.m. Endoscopy live, Part 5

04.00 – 04.20 p.m. Coffee Break in the Industry Exhibition

04.20 – 05.00 p.m. Endoscopy live, Part 6

05.15 – 06.30 p.m. Workshops und discussions - NEW - Registration required, no extra charge.

Seminar für Pflege- und Assistenzpersonal Therapeutische Endoskopie Leitung: Hans-Dieter Allescher Teilnehmer: Ute Pfeifer, Rita Hieber, Martin Mangold, Kollegen aus den drei Hamburger Kliniken

Workshop 1 Advanced polypectomy Chair: Horst Neuhaus Discussants: Dirk Hartmann, Kenneth Binmoeller, Helmut Messmann

Workshop 2 ERCP – Cannulation, precut and sphincterotomy Chair: Paul Fockens Discussants: Jacques Devière, Alexander Meining, Stefan Seewald

Workshop 3 Early tumors in esophagus and stomach Chair: Friedrich Hagenmüller Discussants: Oliver Pech, Uwe Seitz, Naohisa Yahagi

Workshop 4 Overview on Novel Pancreatibiliary Interventions Together with SADE und National Societies Poland, Czech Republic and Hungary Chair: Thomas Rösch Discussants: Lars Aabakken, Jaroslaw Regula, Julius Spicak, István Rácz

6

HONORARY PRESIDENT Prof. Dr. Dr. Manfred StolteKulmbach, Germany

FOUNDING PRESIDENT

Prof. Dr. Nib Soehendra Hamburg, Germany

EXPERTS

HONORARY MEMBER

Kazuhiro SaitoTokyo, Japan

9

9.00 – 10.30 a.m. Friday’s Highlights Part 1 Histology, Evidence and Discussion

Andrea Tannapfel, Bochum Thomas Rösch, Hamburg Friedrich Hagenmüller, Hamburg Siegbert Faiss, Hamburg 10.30 – 11.00 a.m. Coffee Break and visit in the Industry Exhibition

11.00 – 11.45 a.m. Pathology and Endoscopy: Scenes from a Marriage Barrett esophagus, IBD surveillance, resect and discard strategy, serrated adenomas

Andrea Tannapfel, Bochum Gustavo Baretton, Dresden Michael Vieth, Bayreuth Thomas Rösch, Hamburg Friedrich Hagenmüller, Hamburg Siegbert Faiss, Hamburg

11.45 – 12.30 p.m. Friday’s Highlights Part 2 Histology, Evidence and Discussion

Andrea Tannapfel, Bochum Thomas Rösch, Hamburg Friedrich Hagenmüller, Hamburg Siegbert Faiss, Hamburg

12.30 – 01.00 p.m. The most interesting cases from 2014 – follow-up 01.00 – 01.15 p.m. Closing Remarks and Invitation to the

24. ENDOCLUBNORD November 4 and 5, 2016

SATURDAY, NOVEMBER 7, 2015

Prof. Dr. Hans-Dieter AllescherKlinikum Garmisch-Partenkirchen

Garmisch-Partenkirchen, Germany

Prof. Dr. Lars AabakkenRikshospitalet University Hospital

Oslo, Norway

Dr. Jens AschenbeckPraxis

Berlin, Germany

Prof. Dr. Kenneth BinmoellerCalifornia Pacific Medical Center

San Francisco, California, USA

Prof. Dr. Jacques DevièreUniversite Libre des BruxellesHospital Erasme

Brussels, Belgium

Prof. Dr. Axel DignaßAgaplesion Markus Krankenhaus

Frankfurt, Germany

Dr. Julia BertoliniMVZ Hanse Histologikum GmbH

Hamburg, Germany

Prof. Dr. Gustavo B. BarettonUniversitätsklinikum Carl Gustav Carus

Dresden, Germany

8

8

EXPERTS

Salofalk® Tablets are not approved for Crohn‘s disease in all countries. Please refer to your local SPC.

* Crohn‘s Disease Activity Index (CDAI) ≤ 300. 1 Tromm et al., Gastroenterology. 2011;140:425–34

• Targeted release in the terminal ileum and colon ascendens

• High local luminal concentrations due to accelerated release

• Proven efficacy挀挀 in mildly active ileocaecal Crohn’s disease1

Targeted mesalazine for mild ileocaecal Crohn’s disease

www.drfalkpharma.com

Salofalk® Granules 500mg/1000mg/1.5g/3g; Salofalk® 250mg/500mg Gastro-resistant tablets, Salofalk® 250mg/500mg/1g Suppositories, Salofalk® 2g/30ml and 4g/60ml Enemas; Salofalk® 1g Rectal Foam. Active ingredient: mesalazine (5-aminosalicylic acid). Composition: 1 sachet of Salofalk® granules 500mg/1000mg/1.5g/3g contains: active ingredient: 500 mg/1000 mg/1.5 g/3 g mesalazine. Other ingredients: aspartame (E951), carmellose sodium, citric acid, silica colloidal anhydrous, hypromellose, magnesium stearate, methacrylic acid-methyl methacrylate copolymer (1:1) (Eudragit L 100), methylcellulose, cellulose microcrystalline, polyacrylate dispersion 40% (Eudragit NE 40 D containing 2% Nonoxynol 100), povidone K25, simeticone, sorbic acid, talc, titanium dioxide (E171), triethyl citrate, vanilla custard flavouring (containing propylene glycol). 1 tablet of Salofalk® 250mg/500mg contains: active ingredient: 250 mg/500 mg mesalazine. Other ingredients: Calcium stearate, basic butylated methacrylate copolymer (=Eudragit E), methacrylic acid methyl methacrylate copolymer (1:1) (=Eudragit L), glycine, silica col-loidal anhydrous, hypromellose, macrogol 6000, cellulose microcrystalline, sodium carbonate anhydrous, povidone K25, talc. Colouring agents: titanium dioxide (E171), iron oxide hydrate (E172), additionally Salofalk® 500mg tablets: croscarmellose sodium. 1 Salofalk® 250mg/500mg/1g suppository contains: active ingredient: 250 mg/500 mg/ 1 g mesalazine. Other ingredients: hard fat; additionally Salofalk® 500mg suppositories: docusate sodium, cetyl alcohol. 1 enema of Salofalk® 2g/30ml or 4g/60ml contains: active ingredient: 2 g or 4 g mesalazine. Other ingredients: sodium benzoate (E211), potassium metabisulphite (E224), potassium acetate, carbomer 947P, sodium edetate, xanthan gum, purified water. Note: Salofalk® enemas contain sodium benzo-ate and potassium metabisulphite. See patient information leaflet. Salofalk® 1g Rectal Foam: 1 actuation contains: active ingredient: 1 g mesalazine. Other ingredients: sodium metabisulphite (E223), cetostearyl alcohol, polysorbate 60, sodium edetate, propylene glycol. Propellants: propane, n-butane, isobutane. Note: Salofalk® 1g Rectal Foam contains sodium metabisulfite (E223), propylene glycol and cetostearyl alcohol. See patient information leaflet. Indications: Salofalk® granules 500mg/1000mg/1.5g/3g: acute treatment and prevention of recurrence of ulcerative colitis. Salofalk® 250mg/500mg tablets: acute treatment and prevention of recurrence of ulcerative colitis. Acute treatment of Crohn‘s disease. Salofalk® 250mg/500mg/1g suppositories: acute treatment of (1g: mild to moderate) ulcerative colitis confined to the rectum. Additionally Salofalk® 250mg suppositories: prevention of recurrence of ulcerative colitis. Salofalk® 2g/30ml enemas: acute treatment of mild to moderate ulcerative colitis, localised in the rectum and sigmoid colon. Salofalk® 4g/60ml enemas: acute treatment of ulcerative colitis. Salofalk® 1g Rectal Foam: Treatment of active, mild ulcerative colitis of the sigmoid colon and rectum. Contraindications: known hypersensitivity to salicylates or any of the excipients, severe impairment of hepatic or renal function. Pregnancy and lactation: risk-benefit ratio. Additionally for Salofalk® Enemas and Rectal Foam: not to be used in case of sensitive patients (especially for known asthmatics or allergic anamnesis) due to the content of metabisulphite or sodium benzoate. Side effects: headaches, dizziness, peripheral neuropathy, abdominal pain, diarrhea, flatulence, nausea, vomiting, impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency. Hypersensitivity reactions such as allergic exanthema, drug fever, pancolitis, lupus erythematosus syndrome, allergic and fibrotic lung reactions (in-cluding dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), peri- and myocarditis, acute pancreatitis, myalgia, arthralgia, altered blood counts (aplastic anemia, agranulocytosis, pancytopenia, neutropenia, leucopenia, thrombocytopenia), changes in liver function parameters (increase in transaminases and parameters of cholestasis), hepatitis, cholestatic hepatitis, alopecia, oligospermia (reversible). Additionally for Salofalk® 1g Rectal Foam: abdominal distension, anal discomfort, application site irritation, painful rectal tenesmus. Salofalk® 1g Supp.: constipation. Interactions and dosage: see patient information leaflet. Available on prescription only. Date of information: 11/2012

TabletsMesalazine with Crohn’s galenic

11

Prof. Dr. Horst NeuhausEvangelisches KrankenhausDüsseldorf

Düsseldorf, Germany

Dr. Gero MoogGastroenterologische Fachpraxis

Kassel, Germany

Prof. Dr. Helmut MessmannKlinikum Augsburg

Augsburg, Germany

Prof. Dr. Alexander MeiningUniversitätsklinikum Ulm

Ulm, Germany

PD Dr. Oliver MannUniversitätsklinikumHamburg-Eppendorf

Hamburg, Germany

Martin MangoldKlinikum Garmisch-Partenkirchen

Garmisch-Partenkirchen, Germany

Prof. Dr. Ansgar LohseUniversitätsklinikumHamburg-Eppendorf

Hamburg, Germany

Prof. Dr. Stephan HollerbachAllgemeines Krankenhaus Celle

Celle, Germany

Rita Hieber Klinikum Augsburg

Augsburg, Germany

PD Dr. Dirk HartmannSana Klinikum LichtenbergOskar-Ziethen-Krankenhaus

Berlin, Germany

Prof. Dr. Paul FockensAcademic Medical CenterUniversity of Amsterdam

Amsterdam, The Netherlands

Dr. Bernd FeyerabendMVZ Hanse Histologikum GmbH

Hamburg, Germany

13

EXPERTS

A new therapy option to treat Short Bowel Syndrome

NPS Pharma Germany GmbH · The Squaire 12,Am Flughafen · 60549 Frankfurt/MainTel: 069 959 325 208 · E-Mail: info@npsp.de

Recently approved in the EU!

All details and the prescribing information can be found at:

www.npsp.de/arzneimittel

Optimizes the absorptive capacity of the intestine1,2

0BASELINE DAY 21

100

200

300

400

500

600

700

800

900

Vill

us h

eigh

t (

m)

DGEM

S3-GUIDELINESRECO M M E N D E D

References:

1. Jeppesen et al., Gut 2005;54:1224–1231

2. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM323506.pdf

Biopsy of a study participant

Dr. Ute PfeiferEvangelisches Krankenhaus Düsseldorf

Düsseldorf, Germany

PD Dr. Oliver PechKrankenhaus Barmherzige Brüder Regensburg

Regensburg, Germany

Prof. Dr. Karl-Jürgen OldhaferAsklepios Klinik Barmbek

Hamburg, Germany

Dr. Michael Oelckers Albertinen-Krankenhaus

Hamburg, Germany

István RáczPetz Aladar County and Teaching Hospital

Győr, Hungary

Prof. Dr. Jaroslaw Regula Medical Center for Postgraduate Education and Institute of OncologyWarsaw, Poland

Prof. Dr. Hans-Joachim Schulz Sana Klinikum Lichtenberg

Berlin, Germany

Prof. Dr. Britta Siegmund Med. Klinik I, CharitéUniversitätsmedizin Berlin, Campus Benjamin FranklinBerlin, Germany

PD Dr. Uwe Seitz Kreiskrankenhaus Bergstraße

Heppenheim, Germany

Prof. Dr. Stefan Seewald Klinik Hirslanden

Zurich, Switzerland

Prof. Dr. Wolfgang SchwenkAsklepios Klinik Altona

Hamburg, Germany

Dr. Gabriele NiemannHELIOS Klinikum Emil von Behring

Berlin, Germany

www.cookmedical.com

H EMOS TA SIS

© COOK 2014 ESC-WADV-INSTINCT-EN-201409

Instinct™

E N D O S C O P I C H E M O C L I P

Turn up the volume.

Image courtesy of Shou Jiang Tang, MD, University of Mississippi Medical Center, Jackson, MS.

Expand your tissue grasping capabilities with the Instinct Endoscopic Hemoclip. At 16 mm, the jaw span is the widest on the market. And because it is fully adjustable, you can open and close the Instinct clip to securely grasp as much—or as little—tissue as your procedure requires.

For your next clipping procedure, simply follow your instincts to enhanced patient care.

14 15

EXPERTS

Prof. Dr. Naohisa Yahagi Keio University School of Medicine

Tokyo, Japan

Prof. Dr. Michael ViethKlinikum Bayreuth GmbH

Bayreuth, Germany

Prof. Dr. Katharina TiemannMVZ Hanse Histologikum GmbH

Hamburg, Germany

Prof. Dr. Andrea Tannapfel Ruhr-Universität Bochum

Bochum, Germany

Dr. Stefan SteurerUniversitätsklinikumHamburg-Eppendorf

Hamburg, Germany

Prof. Dr. Julius Spicak IKEM -Institute for Clinical and Experimental Medicine

Prague, Czech Republic

16 17

REGISTRATION

Registration fee payment received by Sep 30, 2015 from Oct 1, 2015

Physician € 240,- € 280,- Member bng/ESGE € 200,- € 240,- Assistance (evidence enclosed) € 70,- € 90,-Nurse € 70,- € 90,-Student (evidence enclosed) € 70,- € 90,-

Team Ticket: 1 physician and 2 nurses € 350,- € 390,- 1 physician and 3 nurses € 400,- € 440,- 1 physician and 4 nurses € 430,- € 470,-

In the registration fee coffee breaks and lunches are included.

Please register via our website www.endoclubnord.com or complete the enclosed registration form at the end of this program. The final registration date is November 2, 2015. After this date on site registration only.

On your bank transfer please indicate “ECN 2015” and the name of the participant and transfer funds to the following account:

COCS GmbH, Munich, GermanyHypoVereinsbank Munich, GermanyIBAN: DE30 7002 0270 0039 6131 40 SWIFT/BIC: HYVEDEMMXXXPlease note that we do not cover any bank charges.

For payments received before October 20, 2015 by partici-pants from Germany, Austria and Switzerland the personalcongress documents will be sent by post before the congress. To avoid unnecessary delays the final conferenceprogram and your badge holder will be available in the entrance hall of the CCH.

Cancellation in writing must be received no later than October 20, 2015. A service fee of € 20,- will be deductedfrom the refund amount. Registration fees will not be refunded if cancellations are received at a later date.

Registration

Mode ofPayment

Congress Documents

Cancellation

GENERAL INFORMATION

Congress Presidents Prof. Dr. Thomas Rösch Universitätsklinikum Hamburg-Eppendorf

Prof. Dr. Friedrich Hagenmüller Asklepios Klinik Altona

PD Dr. Siegbert Faiss Asklepios Klinik Barmbek Venue Congress Center Hamburg - CCH Marseiller Straße ∙ 20355 Hamburg, Germany

Congress COCS GmbH – Congress Organisation C. SchäferOrganization Rosenheimer Str. 145c ∙ 81671 Munich, Germany Phone: +49 (0)89 – 89 06 77-0 Fax: +49 (0)89 – 89 06 77-77 E-mail: sandra.reber@cocs.de ∙ www.cocs.de

Opening Hours Thursday, November 5, 2015 4.00 p.m. – 7.00 p.m.Registration Desk Friday, November 6, 2015 8.00 a.m. – 7.00 p.m. Saturday, November 7, 2015 8.00 a.m. – 2.00 p.m.

Internet www.endoclubnord.com

Translation The conference languages are German and English with translation during the main congress.

Certification Confirmation of participation will be issued to all partici- pants at the end of the congress. The congress will be certified by the Ärztekammer (General Medical Council) Hamburg.

Liability The congress organizer will bear no liability for loss, accident, damage or injury to persons or property irrespective of the cause. The client participates at all sessions, tours and events at his/her own risk. Sole place of jurisdiction is Munich, Germany. German law is applicable.

18 19

by train

by car

parking

by HVV(public transport)

The Congress Center Hamburg is right next door to Dammtor InterCity rail station. For further details related to the exclu-sive German Railways offer for ENDOCLUBNORD participants please see page 20.

If you come to CCH - Congress Center Hamburg by car or motor bike, please follow the signs to “Messe/CCH” from all directions.

The CCH offers parking for € 2,- per hour and € 14,- per day.

Dammtor station is right next to CCH, for InterCity trains and S-Bahn. U-Bahn stations Stephansplatz (Opera/CCH) and Gänsemarkt are just a short walk away, on a route that passes through a landscaped park and attractive streets. Youwill be entitled to use Hamburg‘s entire public transport system for the duration of the conference. The network includes buses, “S-Bahn” (overground trains) and “U-Bahn” (under-ground metro system) as well as some of the harbour ferries. Your name badge will be valid as your ticket. See map on page 23.

TRAVELGENERAL INFORMATION

HotelReservation

SMS/E-mailsto the moderators

Photography/ filming

Rooms are reserved under www.hrs.de/endoclubnord. Please note that two other big events are taking place in Hamburg at the same time as the ENDOCLUBNORD and hotels will be booked out early.

Questions or comments during the sessions can be sent via SMS: anounced on siteE-mail: ecn@luxav.org

No photography or filming during lectures or live demons-trations permitted. The organizers will share selected recordings on the website. In case you do not wish to be recorded please advise in advance.

Environment and Climate-Friendly Journey with Deutsche BahnTravel by train from Euro 99 with 100% green power to ENDOCLUBNORD

In cooperation with the COCS GmbH and Deutsche Bahn you travel safely and conveniently to ENDOCLUBNORD!

Your way to save the environment: Travel with 100% green power to your event with Deutsche Bahn long-distance services. We guarantee to get the energy you needed for your journey in Germany from 100% renewable sources.

The price for your Event Ticket for a return trip* to Hamburg is:

2nd class Euro 99 € 1st class Euro 159 €

Our service centre is looking forward to inform you about the ticket price for international journeys. Your ticket is valid from 4th to 9th November 2015.

To book call +49 (0)1806 - 31 11 53** and mention ENDOCLUBNORD as re-ference. Please have your credit card ready when booking. Alternatively, you can also reserve your ticket online at www.bahn.de/Veranstaltungsticket. Your booking will be binding after Deutsche Bahn’s confirmation.

Every time you purchase an Event Ticket with your BahnCard or bahn.bonus Card you can col-lect valuable bonus and status points. Redeem your bonus points by selecting attractive rewards such as free journeys or first-class up-grades. For more information go to www.bahn.de/bahn.bonus

Your price advantages compared to the regular prices***:

e. g. for your journey from(return trip)

1st class – 159 € 2nd class – 99 €

Regular Fare

Your Price Advantage

Regular Fare

Your Price Advantage

Munich Hamburg €460 €301 €284 €185

Frankfurt/M. Hamburg €396 €237 €244 €145

Leipzig Hamburg €330 €171 €204 €105

Cologne Hamburg €314 €155 €194 €95

Berlin Hamburg €252 €93 €156 €57

The COCS GmbH and Deutsche Bahn wish you a pleasant journey!

* An advance booking of at least three days is required. Changes and reimbursement before the first day of validity are possible. Changes and reimbursement conditions at the time of the ticket booking are accord-ing to Conditions of Carriage of the DB of Sparpreis fares. Changes and reimbursement are excluded from the first day of validity onwards. Passengers restrict themselves to a particular train and travel times. For a supplement of Euro 40 full flexible tickets are also available for domestic travels within Germany.** The booking line is available from Monday to Saturday 07:00 am to 10:00 pm. Calls will be charged at Euro 0.20 per call, from mobiles Euro 0.60 per call at maximum. *** Prices are subject to change.20

ARRIVAL ARRIVAL

21

Special offer: Discounted travel with Lufthansa Group Airlines

Lufthansa Group Partner Airlines offer a comprehensive global rou-te network linking major cities around the world. We offer special prices and conditions to participants, visitors, exhibitors, invited guests as well as employees of the Contracting partner and their travel companions.

To make a reservation, please click on: www.lufthansa.com/event-booking_en and enter the access code DE-ZEDLO in the „Access to Your Special Lufthansa Offer“ area. This will open an online booking platform that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

Note: Pop-ups must be enabled otherwise the booking platform window will not open.

These promotional fares are also available through your IATA / ARC travel agent. Travel agents can obtain ticketing instructions by sending an email to lufthansa.mobility@dlh.de and providing the access code as a reference.

23

PUBLIC TRANSPORTATION

Discover our latest stent and hemostasis solutions at our booth on „Endo Club

Nord 2015“ in November. And in case you don`t want to wait that long: You

can get all necessary information on www.micro-tech-europe.com right now.

November will be your lucky month:You`ll meet our innovations.

Eide

lste

dt

Zent

rum

Bönn

ings

tedt

Elle

rau

Qu

ickb

orn

Hör

gens

weg

Burg

wed

el

Tann

enec

k

Has

loh

Qui

ckb

orn

Süd

Schn

else

n

Ulz

bu

rg S

üd

Rich

tung

Neu

mün

ster

/Kie

l/Fl

ensb

urg

Rich

tung

Itze

hoe/

Hus

um

Dau

enh

of

Hor

st

Als

ter

Berl

iner

To

r

Ritt

erst

raße

War

tena

u

Land

weh

r

Bar

mb

ekFr

iedr

ichs

-

ber

g

Korn

weg

(K

lein

Bo

rste

l)

Hoh

enei

chen

Wel

lings

büt

tel

Pop

pen

bü

ttel

Hab

icht

stra

ße

Rüb

enka

mp

(Cit

y N

ord

) Alte

Wöh

r

(S

tad

tpar

k)

Oh

lsd

orf

Seng

elm

anns

traß

e

(

Cit

y N

ord

)

Als

terd

orf

Latt

enka

mp

(

Spor

thal

le)

Hud

twal

cker

stra

ße

Kelli

nghu

sen-

str

aße

Nor

der

sted

t Mit

te

Rich

tung

Neu

mün

ster

Chr

istu

skirc

he

Emili

enst

raße

Ost

erst

raße

Lutt

erot

hstr

aße

Hag

enb

ecks

Tie

rpar

k

Hag

ende

el

Nie

nd

orf M

arkt

Joac

him

-Mäh

l-Str

aße

Schi

pp

elsw

eg

Nie

nd

orf N

ord

Ster

nsch

anze

(Mes

se)

Feld

stra

ße(H

eilig

enge

istf

eld

)

St. P

auli

Sch

lum

pH

olst

enst

raße

Alt

ona Reeperb

ahn

Königstraße

Landungsbrü

cken

Pris

dorf

Elm

shor

n

Lang

enm

oor

Spar

riesh

oop

Bokh

olt

Voßl

och

Barm

sted

t Br

unne

nstr

aße

Bar

mst

edt

Pin

neb

erg

Torn

esch

Alv

eslo

he

Lang

eln

Buck

horn

Hoi

sbüt

tel

Oh

lste

dt

Volk

sdor

f

Alte

r Tei

chw

eg

Stra

ßbur

ger S

traß

e

Wan

dsb

ek

Mar

kt

Wan

dsb

ek-

Gar

ten

stad

t

Trab

renn

bah

n

Farm

sen

Bern

e

Mei

endo

rfer

Weg

Buchenkam

pAhre

nsburg

W

est

Ahrensb

urg

O

stSch

malenbeck

Kiekut

Großhansdorf

Bad

Old

eslo

eKu

pfe

rmüh

leBa

rgte

heid

e

Ah

ren

sbu

rg

Rei

nfe

ld

Rich

tung

Lüb

eck

Wah

lste

dt

Alte

ngör

s

Bad

Seg

eber

g

Wak

endo

rfFr

esen

bur

g

Ric

klin

g Fahr

enkr

ugRich

tung

Neu

mün

ster

Roth

enb

urgs

ort

Billw

erde

r-M

oorf

leet

Mitt

lere

r Lan

dweg

Ber

ged

orf

Reinbek

Wohlto

rfAum

ühle

Friedric

hsruh

Schwarze

nbekMüsse

n

Rich

tung

Sc

hwer

in/R

osto

ck

Bü

chen

Rich

tung

Uel

zen

Lün

ebu

rg

Laue

nbur

g

Dannenberg O

st

Eche

m

Tief

stac

k

Mec

kelfe

ldM

asch

enSt

elle

Win

sen

Radbruch

Bardowick

Vastorf Bavendorf

DahlenburgGöhrd

e

Wendisc

h Evern

Neetzendorf

Hitt

feld

Klec

ken

Bu

chh

olz

Har

bu

rg

Suer

hop

Hol

m-S

epp

ense

nBü

senb

acht

al

Han

del

oh

Sprötze

Tost

edt

Rich

tung

Sol

tau

Harburg

Rath

aus

Heimfeld

Neuwiedenthal

Rich

tung

Bre

men

Bargste

dt

Brest-

Aspe

Kutenholz

Apensen

Ruschwedel

Harsefeld

Rich

tung

Br

emer

have

nN

eukl

oste

r

Hor

nebu

rg

Dol

lern

Aga

then

burg

Stad

e

Ham

mah

Him

mel

-p

fort

en

Rich

tung

Cu

xhav

en

Neugraben

Neu Wulm

storf

Thes

dorf El

bg

aust

raß

e

Mön

ckeb

ergs

traß

e

Meß

ber

g

Übersee-

q

uartier

Stei

nst

raß

e

Rödingsm

arkt

BaumwallM

esse

halle

n

Gän

sem

arkt

(Op

er)

Step

hans

plat

z(O

per/

CCH

)

Stad

thau

s-br

ücke

Epp

endo

rfer

Baum

H

ohel

uft-

b

rück

e

Klos

ters

tern

Hal

lers

traß

eD

amm

tor

(Mes

se /

CCH

)

Borgweg

(S

tadtp

ark)

Saarland-

st

raße

Sierichstr

aße

Lohm

ühle

nstr

aße

Ham

bur

ger S

traß

e

Mun

dsb

urg

Lüb

ecke

r Str

aße

Uhl

ands

traß

e

Deh

nhai

de

Rahl

sted

t

Tonn

dorf

Wan

dsb

ek

Rich

tung

Lüb

eck

Möl

ln

Rat

zeb

urg

Hal

sten

bek

Krup

unde

r

Alle

rmöh

e

Net

teln

burg

Has

selb

rook

Gro

ßb

erei

ch

Ham

bu

rg (R

ing

e A

B)

Gro

ßb

erei

ch

Ham

bu

rg (R

ing

e A

B)

Gre

ater

Ham

bu

rg A

rea

(far

e ri

ng

s A

B)

Moo

rbek

halle

(S

chul

zent

rum

Nor

d)

Ash

ause

n

Och

sen

zoll

Fuh

lsb

ütt

el N

ord

Klei

n Bo

rste

l

Kalte

nkirc

hen

Süd

Nüt

zen

Bad

Bram

sted

t Kur

haus

Boo

sted

t

Rich

tweg

Gar

sted

t

Kiw

ittsm

oor

Lang

enho

rn N

ord

Lang

enho

rn M

arkt

Fuhl

sbüt

tel

Mee

sche

nsee

Frie

dric

hsga

be

Qui

ckb

orne

r Str

aße

Has

lohf

urth

Gro

ßena

spe

Wie

mer

sdor

fB

ad B

ram

sted

t

Lent

föhr

den

dode

nhof

Kal

ten

kirc

hen

Hen

sted

t-U

lzb

urg

Hol

sten

ther

me

Die

bst

eich

Lang

enfe

lde

Eid

elst

edt

Stel

linge

n

Are

nen

Fischbek

Wan

dsb

eker

C

hau

ssee

Ham

bu

rgA

irp

ort

(Flu

ghaf

en)

Gar

tenh

olz

Burgstr

aßeHam

mer

K

irche Rauhes H

ausHorn

er Rennbahn

Legienstraße Bill

stedt M

erkenstr

aßeSte

infurth

er Alle

e

Müm

melm

annsberg

Jun

gfe

rnst

ieg

Wedel

Rissen Sülldorf Ise

rbro

okHoch

kamp

BlankeneseKlein Flottb

ek

(Bota

nischer G

arten)

Othm

arschen

Bahrenfeld

Ham

mer

bro

ok(C

ity

Süd

)

Wilh

elm

sbur

g

Vedd

el(B

allin

Stad

t)

Hau

pt-

bahn

hof

Cent

ral

Stat

ion

Nor

d

Süd

Leitsta

deHitz

acker

Buxtehude

Rat

hau

s

HafenCity

Universitä

t

Hal

test

elle

n

Sch

nel

lbah

n-/

Reg

ion

alve

rkeh

rR

apid

Tra

nsi

t-/R

egio

nal

Rai

l-Sta

tio

ns

Gre

nze

Gro

ßber

eich

Ham

bur

g (R

inge

AB)

Gre

ater

Ham

bu

rg A

rea

Bo

un

dar

y

nic

ht

im H

VV

ou

tsid

e H

VV

net

wo

rk

Park

en u

nd

Rei

sen

par

k an

d r

ide

Nu

r ze

itw

eilig

/lim

ited

ser

vice

sBa

rrie

refr

eier

Zug

ang

zude

n Sc

hnel

lbah

nen

Info

s zu

m b

arrie

refr

eien

Zuga

ng z

u de

n Re

gion

alba

hnen

unte

r Tel

. 040

-19

449

Barr

ier-

free

acc

ess

to th

e ra

pid

tran

sit t

rain

sIn

form

atio

n on

bar

rier-

free

ac

cess

to th

e re

gion

al tr

ains

on te

l 040

-19

449

Regi

onal

exp

ress

linie

n ha

lten

nich

tan

jed

em B

ahnh

ofN

ot a

ll re

gio

nal t

rain

s st

op a

t all

stat

ions

swit

chh

Punk

teFe

rnb

ahn

ho

fM

ain

-Lin

e St

atio

n

St

and

: 1

4.1

2.2

01

4©

HV

V

Sch

nel

lbah

n-/

Reg

ion

alve

rkeh

rR

apid

Tra

nsi

t/R

egio

nal

Rai

l

04

0-1

9 4

49

ww

w.h

vv.d

e In

form

atio

n .

Fah

rplä

ne

| Tim

etab

les

. Ser

vice

RE

7 / R

E70

/ R

B71

RE

6 / R

B61

/ R

B71

RE6 / RE7 / R

E70 / RB61 / R

B71

RE7 / RE70 / RB71

RE

6 / R

B 7

1

RE

5R

E5

RE3 / RE4 / RE5 RB31 / RB41

RE7

/ RE

70 /

RB

61

RE4 / RB41

RE

4 / R

B41 R

B38

RB

38

RB38

RE

4 / R

B41

RE

5

RE5

RB

33

RB

33

RB33

RE

RB

32

RB32

RE

3

RE

3 / R

B31

RB

31 /

RB

32

/ RE

83

RE

1

RE

1

RE

1 / R

B11

RB

11

RE3 / RB31

RE1

RE83

RE83

RE8 / RE80 / RB81

RE8 / RE80 / R

B81

RE

83

RE

8 / R

E80

RB

81 /

RB

82

RB

82

RB82

RB11

25

Barrx™ RFA System

bnx™ FNA System

Bravo® pH Monitoring System

Digitrapper® pH-Z Monitoring System

ManoScan® HRM System

PillCam® Platform

SmartPill® Motility Monitoring System

One single solution for the continuous care of patients

GI Solutions - Advancing the Gastrointestinal Care ContinuumGI solutions brings together three innovative companies – Barrx Medical, Beacon Endoscopic and Given Imaging – to offer gastroenterologists a single-destination diagnostic and therapeutic solution covering the GI care continuum.

Partner with GI Solutions to benefit from improved care and outcomes for your patients, effective diagnostic and treatment options, and an efficient system designed to help lower costs.

Screening Diagnosing Treating Monitoring

COVIDIEN, COVIDIEN with logo, Covidien logo and positive results for life are U.S. and internationally registered trademarks of Covidien AG. Other brands are trademarks of a Covidien company. © 2014 Covidien.

Discover more at www.covidien.com/gisolutions

Adv_a5_vert.indd 1 09/03/15 13:03

CITY MAP

© M

arcu

s Ven

zke

SPONSORS

The ENDOCLUBNORD is grateful for the support of its sponsors:

27

Our benefits Waterjet elevation prior to APC ablation Thermal protection of the muscularis Limited APC penetration depth, minimized risk of stricture

Targeted, dynamic APC application; healthy epithelium is preserved

Barrett ablation using HybridAPC

ERBE Elektromedizin GmbH | Tübingen | Telefon +49 7071 755-400 | www.erbe-med.com

For further information on our complete range of products, visit our home page.

ELEVATION AND ABLATION USING JUST ONE INSTRUMENT

Benefits of the HybridAPC probe Cost-effective disposable instrument With proven APC and waterjet functions No instrument change for elevation and ablation

One instrument for all Barrett localizations and esophagus lumina

AD_ERBE_HybridAPC_A5_en.indd 1 16.03.2015 10:57:56

Olympus Deutschland GmbH, Hamburg

AbbVie Deutschland GmbH & Co. KG, Wiesbaden

Cook Deutschland GmbH, Mönchengladbach

Covidien Deutschland GmbH, Hamburg

Erbe Elektromedizin GmbH, Tübingen

Dr. Falk Pharma GmbH, Freiburg

marpinion Market Research GmbH, Oberhaching

Micro-Tech Europe GmbH, Düsseldorf

Norgine GmbH, Marburg

NPS Pharma Germany GmbH, Frankfurt am Main

Recordati Pharma GmbH, Ulm

Takeda Pharma Vertrieb GmbH & Co. KG, Berlin

Without engagement - status print date

24

Please cut off and send in a window envelope.

Registration also at: www.endoclubnord.com

REGISTRATION

Next-Generation Communication with Physicians

HELP MAKE A DIFFERENCE BY BECOMING AN OPINION LEADER!

marpinion®: the new approach to communicating with physicians.

Come see us at Endo Club Nord 2015 – your personal iPad is waiting for you! We’ll demonstrate our innovative new app and show how you too can benefi t from marpinion®. If you like, we’ll also be happy to visit you in your practice with no further obligation on your part. Just give us a ring!

marpinion Market Research GmbH | Rai� eisenallee 16 | 82041 Oberhaching | Phone +49 89 1 222 836-800 | www.marpinion.de | info@marpinion.de

MAR_Anzeige_A5_EN_DV_AFU.indd 1 27.02.15 15:20

I will participate at the ENDOCLUBNORD 2015

payment received by Sep 30, 2015 from Oct 1, 2015

Physician € 240,- € 280,- Member of bng € 200,- € 240,- Member of ESGE € 200,- € 240,- Assistance (evidence enclosed) € 70,- € 90,- Nurse € 70,- € 90,- Student (evidence enclosed) € 70,- € 90,-

Team-Ticket

1 physician and 2 nurses € 350,- € 390,- 1 physician and 3 nurses € 400,- € 440,- 1 physician and 4 nurses € 430,- € 470,-

Name of the nurses attending (last name, first name):

1.

2.

3.

4.

I take part on Friday, November 6, 2015, 05.15 p.m. to 06.30 p.m:

Seminar für Pflege- und Assistenzpersonal

Workshop 1 - Advanced polypectomy

Workshop 2 - ERCP – Cannulation, precut and sphincterotomy

Workshop 3 - Early tumors in esophagus and stomach

Workshop 4 - Overview on Novel Pancreatibiliary Interventions

Please deposit the total amount to the account indicated below:

COCS GmbH, Munich, Germany

HypoVereinsbank München

IBAN: DE30 7002 0270 0039 6131 40 · SWIFT/BIC: HYVEDEMMXXX

Keyword: ECN2015 and name of participant

Please note that we do not cover any bank charges.

Date, Signature

NEW:Workshops on Friday

M

s. M

r.

Pr

of.

P

D D

r.

D

r.

Last

Nam

e

Firs

t N

ame

Hos

pita

l/In

stitute

/Pra

ctic

e

Dep

artm

ent

Str

eet

Zip

Cod

e

City

Are

a Cod

e

Phon

e

E-m

ail

Sta

tist

ics:

O

ffice

-bas

ed p

hysi

cian

H

ospi

tal-ba

sed

phys

icia

n

Spe

cial

isat

ion:

G

astr

oente

rolo

gy S

urg

ery

In

tern

al m

edic

ine

O

ther

s

Reg

iste

r by

post

or

onlin

e: w

ww

.endocl

ubnord

.com

CO

CS G

mbH

Con

gres

s O

rgan

isat

ion C

. Sch

aefe

rRose

nhei

mer

Str.

145c

81671 M

unic

hG

erm

any

REG

ISTRATIO

N

© 2014 Takeda Pharma Vertrieb, GmbH & Co. KG

Ulcerative Colitis and Crohn’s Disease:

TREAT WITH PRECISION AT THE SITE OF INFLAMMATION

GUT-SELECTIVE

TREAT WITH PRECISION AT THE SITE OF INFLAMMATION

GUT-SELECTIVE

Lasting remission1 – 3

Good tolerability profi leGood tolerability profi le1 – 31 – 3

The fi rst ever gut-selective integrin receptor antagonist for moderately to severely active ulcerative colitis and Crohn’s disease1 – 4

Approved for use in patients following conventional therapy or anti-TNF therapy1

Entyvio® 300 mg powder for concentrate for solution for infusionActive substance: vedolizumab. Description: Active ingredient: Each vial contains 300 mg of vedolizumab; after reconstitution, each mL solution for infusion contains 60 mg vedolizumab. Excipients: L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose, polysorbate 80. Therapeutic indications and posology: Ulcerative colitis: Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Crohn’s disease: Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Contraindications: Hypersensitivity to the active substance or to any of its excipients. Active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML). (see SmPC section 4.4) Adverse reactions: Very common: nasopharyngitis, headache, arthralgia; Common: bronchitis, gastroenteritis, upper respira-tory tract infection, infl uenza, sinusitis, pharyngitis, paresthesia, hypertension, oropharyngeal pain, nasal congestion, cough, anal abscess, anal fi ssure, nausea, dyspepsia, constipation, abdominal distension, fl atulence, haemorrhoids, rash, pruritus, eczema, erythema, night sweats, acne, muscle spasms, back pain, muscular weakness, fatigue, pyrexia; Uncommon: respiratory tract infections, vulvovaginal candidiasis, oral candidiasis, folliculitis, infusion site reaction (incl. infusion site pain and infusion site irritation), infusion related reaction chills, shivering, feeling cold. During the second infusion, one case of a serious infusion related reaction was reported by a Crohn’s disease patient during the second infusion (symptoms reported were dyspnea, bronchospasm, urticaria, fl ushing, rash, as well as, increased blood pressure and heart rate) and was managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. Infections: In controlled and open-label long-term extension studies in adults with vedolizumab, serious infections have been reported, which include tuberculosis, sepsis (some fatal), salmonella sepsis, listeria meningitis, and cytomegaloviral colitis. Malignancy: Overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment.. However, the number of malignancies in the clinical trials was small; long-term exposure was limited. Long-term safety evaluations are ongoing. For drug interactions and other information, see SmPC. Prescription only. EU marketing authorisation holder: Takeda Pharma A/S, Taastrup, Dänemark. Contact address of the pharmaceutical company in Germany: Takeda GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Tel.: 0800 825 3325, medinfo@takeda.de. 05/2014

1. Entyvio® Summary of Product Characteristics. 05/2014. 2. Feagan BG, et al. N Engl J Med. 2013; 369(8): 699–710 3. Sandborn WJ, et al. N Engl J Med. 2013; 369(8): 711–721 4. Wyant T, et al. Gut. 2014; 0: 1–7. doi: 10.1136/gutjnl-2014-307127

Ved-15-013_Anzeige_Englisch_148x210_110315_RZ.indd 1 11.03.15 11:50